BioPharma

The healthcare company faces legal actions from tens of thousands of plaintiffs, including women suffering from ovarian cancer and others with mesothelioma, alleging that its baby powder and other talc products contained asbestos and caused cancer.

Competition watchdog found company’s ‘excessive and unfair’ prices cost NHS almost £30m extra over 10 years.

Private equity firms Cinven and Hg have been fined by the U.K.’s competition watchdog after a pharmaceutical firm they once owned was found to have overcharged for crucial drugs.

Pfizer expects an adjusted pretax profit in the high 20% range of revenue for the vaccine.

Drug companies almost always publish clinical trial results in a peer-reviewed journal before obtaining FDA approval, but Biogen still hasn't done so for Aduhelm.

A civil opioid trial in West Virginia will hold closing arguments on Tuesday. It comes amid the debate over whether corporations will be held accountable for their role in the addiction crisis.

The case is part of long-running controversy over EpiPen prices.

Stamford, Connecticut-based Purdue said: “More than 95% of the 120,000-plus votes submitted” were in favor of the reorganization plans.

Many healthcare reforms have surfaced over the past two decades, but very few have become law.

Opdivo's 2017 clearance in liver cancer was a milestone, representing the first time an immunotherapy had become available to treat the disease.

Shionogi starts human trials for a once-a-day drug designed to neutralize the coronavirus in less than a week.

Bylvay will come with an eye-popping average list price of $385,000 a year.

After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million.

Facing a host of challenges, Aduhelm’s makers Biogen and its partner Eisai are taking a page right out of a classic marketing playbook: Run an educational campaign directed at the consumer.

The settlement came just days before the case was set to go to trial to decide damages, in which plaintiffs were expected to seek $2.4 billion.